First-in-human study of SGN-B7H4V, a B7-H4-directed vedotin ADC, in patients with advanced solid tumors: Preliminary results of a phase I study (SGNB7H4V-001)

被引：9

作者：

Perez, C. A. ^{[1
]}

Henry, J. T. ^{[2
]}

Lakhani, N. ^{[3
]}

Call, J. A. ^{[4
]}

Hamilton, E. P. ^{[5
]}

Colon-Otero, G. ^{[6
]}

Diamond, J. R. ^{[7
]}

O'Neil, B. ^{[8
]}

Kalyan, A. ^{[9
]}

Sonpavde, G. P. ^{[10
]}

Candilejo, I. Moreno ^{[11
]}

Awan, A. A. ^{[12
]}

Fontana, E. ^{[13
]}

Xu, P. ^{[14
]}

Zhang, F. ^{[15
]}

Nazarenko, N. ^{[16
]}

Patnaik, A. ^{[17
]}

机构：

[1] Univ Cent Florida, Lake Nona Canc Ctr, Florida Canc Specialists, Sarah Cannon Res Inst, Orlando, FL 32816 USA

[2] HealthONE, Sarah Cannon Res Inst, Drug Dev Unit, Denver, CO USA

[3] START Midwest, Dev Therapeut, Grand Rapids, MI USA

[4] START Mt Reg, Dev Therapeut, West Valley City, UT USA

[5] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA

[6] Mayo Clin, Med Oncol, Jacksonville, FL 32224 USA

[7] Univ Colorado, Univ Colorado Hosp, Aurora, CO USA

[8] Community Hlth Network, Hematol & Med Oncol, Indianapolis, IN USA

[9] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Div Hematol & Oncol, Chicago, IL 60611 USA

[10] AdventHlth Canc Inst, Genitourinary Oncol, Celebration, FL USA

[11] START Madrid CIOCC, Ctr Integral Oncol Clara Campal, Madrid, Spain

[12] Ottawa Hosp Res Inst, Med Oncol, Ottawa, ON, Canada

[13] Sarah Cannon Res Inst SCRI UK, Drug Dev, London, England

[14] Seagen Inc, Biostat, Bothell, WA USA

[15] Seagen Inc, Quantitat Pharmacol & Disposit, Bothell, WA USA

[16] Seagen Inc, Global Drug Dev, Bothell, WA USA

[17] START San Antonio, Dev Therapeut, San Antonio, TX USA

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.1846

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

660MO

引用

页码：S464 / +

页数：2